$ZTS (Zoetis Inc.)

$ZTS {{ '2016-03-31T13:30:45+0000' | timeago}} • Announcement

Animal health company $ZTS said it was granted a conditional license for Avian Influenza Vaccine, H5N1 Subtype, Killed Virus by the USDA. The vaccine is for use in chickens to help prevent disease caused by avian influenza H5N1.The conditional license was granted on the demonstration of a reasonable expectation of efficacy based on serology data.

$ZTS {{ '2017-08-08T18:36:56+0000' | timeago}} • Webcast

$ZTS stated that its key markets in Europe performed well in 2Q17, the UK and Germany leading with 12% and 8% operational growth respectively. The growth was driven primarily by strong Apoquel sales.

$ZTS {{ '2017-08-08T15:06:46+0000' | timeago}} • Infographic

$ZTS Zoetis, Inc Segment Revenue Comparison Q2 2017

$ZTS {{ '2017-08-08T11:57:37+0000' | timeago}} • Announcement

$ZTS revenue in the US segment was $623MM in 2Q17, an increase of 5%, as sales of companion animal products grew 7%. Meanwhile, in the International segment, a 12% growth in companion animal products lifted revenue 5% to $634MM.

$ZTS {{ '2017-08-08T11:44:20+0000' | timeago}} • Announcement

$ZTS updated its guidance for FY17, and now expects revenue between $5.15-5.25Bil. While GAAP EPS is anticipated between $2.12 and $2.21, adjusted diluted EPS is predicted to be $2.30-2.37.

$ZTS {{ '2017-08-08T11:39:52+0000' | timeago}} • Announcement

Animal health company $ZTS reported 2Q17 revenue of $1.3Bil, up 5%, helped by higher sales in companion animal products in both the US and International segments. Net income grew 10% to $247MM, or $0.50 per share. On a adjusted basis, $ZTS earned $261MM, or $0.53 per share during the quarter.

$ZTS {{ '2017-08-04T18:38:36+0000' | timeago}} • Announcement

$ZTS, an animal health company, has appointed Linda Rhodes to its BoD, effective Aug. 3, 2017. She will serve on the Quality and Innovation Committee of the Board.

$ZTS {{ '2017-07-31T15:45:00+0000' | timeago}} • Announcement

$ZTS has completed the acquisition of $NVET, a biologic therapeutics company. Under the terms of the transaction, $NVET shareholders will receive $6.72 per share representing an aggregate equity valuation of approx. $85MM.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$ZTS {{ '2017-05-11T20:52:27+0000' | timeago}} • Announcement

$ZTS BoD declared 3Q17 dividend of $0.105 per share, payable to holders of the company’s common stock. The dividend is payable on Sept. 1, 2017, to holders of record on June 15, 2017.

$ZTS {{ '2017-05-11T11:47:10+0000' | timeago}} • Announcement

$ZTS announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich. $ZTS will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. $ZTS expects to add up to 45 manufacturing positions in the next 3 years.

$ZTS {{ '2017-05-04T12:18:44+0000' | timeago}} • Announcement

In 1Q17, $ZTS' revenue in the US segment was $605MM, a growth of 4% YoY. Meanwhile, revenue in the International segment rose 8% on a reported basis and 9% operationally to $615MM.

$ZTS {{ '2017-05-04T12:14:52+0000' | timeago}} • Announcement

$ZTS reaffirmed its guidance for FY17. Revenue is expected between $5.1Bil and $5.225Bil, while EPS is estimated between $2.08 and $2.20. Adjusted EPS is predicted in the range of $2.26-2.36.

$ZTS {{ '2017-05-04T12:11:09+0000' | timeago}} • Announcement

Animal health company $ZTS posted 17% improvement in net income in 1Q17, helped by a 6% hike in revenue to $1.2Bil. Net income was $238MM, or $0.48 per share, compared to $204MM, or $0.41 per share in the year-over period. On an adjusted basis, $ZTS earned $0.53 per share.

$ZTS {{ '2017-04-27T13:42:42+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab). Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more.

$ZTS {{ '2017-04-13T14:44:27+0000' | timeago}} • Announcement

$ZTS will acquire $NVET for $6.72 in cash per ordinary share, which values the entire issued and to be issued ordinary share capital of Nexvet at approx $85MM. This per share purchase price represents a 66% premium over Nexvet’s April 12, 2017 closing price. The acquisition will be completed in H2 of 2017.

$ZTS {{ '2017-02-16T14:30:06+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company a license for Stronghold Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats.

$ZTS {{ '2017-02-16T14:23:52+0000' | timeago}} • Webcast

$ZTS expects to exceed its target of $300MM in savings for 2017. Also for the year, the company has planned to initiate direct-to-consumer marketing and advertising campaigns in the U.S. for its animal products.

$ZTS {{ '2017-02-16T14:17:40+0000' | timeago}} • Webcast

$ZTS said it has returned $488MM in excess capital to shareholders through dividends and share repurchase in 2016. In addition, the company has announced $1.5Bil multi-year share repurchase program beginning in 2017.

$ZTS {{ '2017-02-16T13:02:34+0000' | timeago}} • Announcement

For FY17, $ZTS expects revenue to be in the range of $5.100-5.225Bil. The company expects reported diluted EPS to be between $2.08-2.20 per share. Adjusted diluted EPS is expected to be about $2.26-2.36.

$ZTS {{ '2017-02-16T13:00:43+0000' | timeago}} • Announcement

During 4Q16, $ZTS's revenue in the U.S. segment was $631MM, 1% down compared with 4Q15, reflecting the impact of fewer calendar days and product rationalizations. Revenue in the International segment rose 2% to $636MM, the growth reflects the impact of product rationalizations.

Recent Transcripts

ICCC (ImmuCell Corp.)
Monday, August 14 2017 - 8:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, August 10 2017 - 12:00pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
TSRO (Tesaro, Inc.)
Tuesday, August 8 2017 - 8:15pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, August 1 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ADM (Archer-Daniels-Midland Company)
Tuesday, August 1 2017 - 1:00pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
HSKA (Heska Corporation)
Monday, July 31 2017 - 3:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
ABAX (Abaxis, Inc.)
Thursday, July 27 2017 - 8:15pm
MDXG (MiMedx Group, Inc.)
Thursday, July 27 2017 - 2:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm

AlphaGraphics you may like